Related Experiment Video
Updated: Jul 5, 2025
12:48
PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
Published on: December 27, 2013
65.3K
Good's Buffer Based Highly Biocompatible Ionic Liquid Modified PLGA Nanoparticles for the Selective Uptake in Cancer
Gagandeep Singh1, Gaya S Dasanayake1, Claylee M Chism1
1Department of Chemistry and Biochemistry, University of Mississippi, University, MS 38677.
Materials Chemistry Frontiers
|January 11, 2024
Summary
New biocompatible ionic liquids coat nanoparticles, enhancing targeted delivery to cancer cells. This breakthrough improves drug delivery efficacy by selectively increasing uptake in cancer cells while reducing it in healthy cells.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Drug Delivery Systems
Background:
- Developing safe and effective drug delivery systems remains a significant challenge in medicine.
- Poly(lactic-co-glycolic acid) (PLGA) nanoparticles are widely used but require surface modification for targeted delivery.
- Ionic liquids offer unique properties that can be leveraged for advanced biomedical applications.
Purpose of the Study:
- To synthesize and characterize novel biocompatible Good's buffer-based ionic liquids (GBILs).
- To modify the surface of PLGA nanoparticles with GBILs for enhanced drug delivery.
- To evaluate the cellular uptake and bio-interface interactions of GBIL-modified PLGA nanoparticles.
Main Methods:
- Synthesis of 20 GBILs and their characterization.
- Surface coating of PLGA nanoparticles using nanoprecipitation-sonication.
- Characterization of nanoparticles using dynamic light scattering (DLS) and proton nuclear magnetic resonance (¹H NMR) spectroscopy.
- Assessment of interactions with serum proteins (SDS-PAGE, LCMS) and red blood cells (RBCs).
- Evaluation of cellular uptake in human triple-negative breast cancer cells (MDA-MB-231) and normal breast cells (MCF-10A).
Main Results:
- GBILs were successfully synthesized and used to modify PLGA nanoparticles.
- GBIL-modified PLGA nanoparticles exhibited selective cellular uptake, favoring MDA-MB-231 cancer cells over MCF-10A normal cells.
- Cholinium N,N-bis(2-hydroxyethyl)-2-aminoethane sulfonate (CBES)-coated PLGA NPs showed 60.7% uptake in cancer cells versus 27.3% in normal cells.
- Surface modification with GBILs doubled cancer cell uptake while reducing normal cell uptake.
Conclusions:
- GBIL-modified nanoparticles represent a versatile platform for targeted drug delivery and gene therapy.
- Tailoring nanoparticle surface properties with GBILs can enhance cellular uptake and achieve site-specific delivery.
- This formulation technique shows promise for targeting specific cell types and warrants further exploration for therapeutic applications.
